Nuvalent, Inc. (NUVL), a biotechnology company specializing in cancer therapies, announced on Monday the launch of a $350 million underwritten public offering of its Class A shares. All shares in this offering are being issued by Nuvalent.
The company anticipates providing the underwriters with a 30-day option to acquire up to an additional 15% of the Class A shares initially offered.
J.P. Morgan, TD Cowen, Jefferies, and Stifel are serving as joint book-running managers for this offering.
